Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination.
Tocotrienols are a form of vitamin E, having an unsaturated isoprenoid side-chain rather than the saturated side-chain of tocopherols. The tocotrienol-rich fraction (TRF) from palm oil contains alpha-tocopherol and a mixture of alpha-, gamma- and delta-tocotrienols. Earlier studies have shown that tocotrienols display anticancer activity. We previously reported that TRF, alpha-, gamma- and delta-tocotrienols inhibited proliferation of estrogen receptor-negative MDA-MB-435 human breast cancer cells with 50% inhibitory concentrations (IC50) of 180, 90, 30 and 90 microg/mL, respectively, whereas alpha-tocopherol had no effect at concentrations up to 500 microg/mL. Further experiments with estrogen receptor-positive MCF-7 cells showed that tocotrienols also inhibited their proliferation, as measured by [3H] thymidine incorporation. The IC50s for TRF, alpha-tocopherol, alpha-, gamma- and delta-tocotrienols were 4, 125, 6, 2 and 2 microg/mL, respectively. Tamoxifen, a widely used synthetic antiestrogen inhibits the growth of MCF-7 cells with an IC50 of 0.04 microg/mL. We tested 1:1 combinations of TRF, alpha-tocopherol and the individual tocotrienols with tamoxifen in both cell lines. In the MDA-MB-435 cells, all of the combinations were found to be synergistic. In the MCF-7 cells, only 1:1 combinations of gamma- or delta-tocotrienol with tamoxifen showed a synergistic inhibitory effect on the proliferative rate and growth of the cells. The inhibition by tocotrienols was not overcome by addition of excess estradiol to the medium. These results suggest that tocotrienols are effective inhibitors of both estrogen receptor-negative and -positive cells and that combinations with tamoxifen should be considered as a possible improvement in breast cancer therapy.
Guthrie
N
N
Department of Biochemistry, The University of Western Ontario, London, Canada.
Gapor
A
A
Chambers
A F
AF
Carroll
K K
KK
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D001943:Breast Neoplasms; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002839:Chromans / Q000494:pharmacology; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology*; D004347:Drug Interactions; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000073878:Palm Oil; D010938:Plant Oils / Q000737:chemistry / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000378:metabolism*; D013629:Tamoxifen / Q000494:pharmacology*; D024508:Tocotrienols; D014407:Tumor Cells, Cultured; D014810:Vitamin E / Q000031:analogs & derivatives / Q000494:pharmacology*
D018931:Antineoplastic Agents, Hormonal; D000975:Antioxidants; D002839:Chromans; D004042:Dietary Fats, Unsaturated; D004965:Estrogen Antagonists; D010938:Plant Oils; D011960:Receptors, Estrogen; D024508:Tocotrienols; D013629:Tamoxifen; D014810:Vitamin E; C082097:tocotrienol, delta; C013649:plastochromanol 8; D000073878:Palm Oil; C082032:tocotrienol, alpha